Axicabtagene ciloleucel (axi-cel) CAR-T for r/r FL — single infusion after lymphodepletion (ZUMA-5)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | None declared |
|---|
| ID | REG-CAR-T-AXICEL-FL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-FL-2024 SRC-NCCN-BCELL-2025 |
Notes
ZUMA-5 trial (Jacobson 2022): r/r FL after ≥2 prior lines (incl anti-CD20 + alkylator) — ORR ~94%, CR ~79%, median DOR not reached at 4-year follow-up (~57% of complete responders remain in remission at 4 years). Best response rates of any 3L+ FL therapy. Toxicity similar to ZUMA-1 (DLBCL) but lower-grade in indolent setting: Grade ≥3 CRS ~7%, Grade ≥3 ICANS ~19%. Centre must be FACT/JACIE/ REMS-accredited. Bridging therapy if needed during 3-4 week manufacturing window. Ukraine: not registered — access barrier dominant. Liso-cel (TRANSCEND FL-001) is alternative CAR-T product with lower CRS/ICANS — separate Regimen entity (future).
Used By
Indication
IND-FL-3L-AXICEL-CART- IND-FL-3L-AXICEL-CART